 HCSGs Q2 EPS missed Street estimates by 0.16, and 0.15 of that was down to issues tied to Genesis Healthcare, SEC-related costs, and other settlement fees tied to employment issues. Genesis-related pricing headwinds will persist until the end of this year, conversely, the company will likely receive a 50m incremental benefit on account of better cross-selling opportunities. 